Latest Insider Transactions at Abb Vie Inc. (ABBV)
This section provides a real-time view of insider transactions for Abb Vie Inc. (ABBV). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of AbbVie Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of AbbVie Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 28
2024
|
Richard A Gonzalez CHAIRMAN OF THE BOARD AND CEO |
SELL
Bona fide gift
|
Direct |
6,000
-1.16%
|
-
|
May 03
2024
|
Jennifer L. Davis |
BUY
Grant, award, or other acquisition
|
Direct |
1,322
+50.0%
|
-
|
May 03
2024
|
Frederick H Waddell |
BUY
Grant, award, or other acquisition
|
Direct |
1,322
+4.55%
|
-
|
May 03
2024
|
Glenn F Tilton |
BUY
Grant, award, or other acquisition
|
Direct |
1,322
+2.56%
|
-
|
May 03
2024
|
William H.L. Burnside |
BUY
Grant, award, or other acquisition
|
Direct |
1,322
+4.88%
|
-
|
May 03
2024
|
Rebecca B Roberts |
BUY
Grant, award, or other acquisition
|
Direct |
1,322
+9.55%
|
-
|
May 03
2024
|
Melody B Meyer |
BUY
Grant, award, or other acquisition
|
Direct |
1,322
+7.96%
|
-
|
May 03
2024
|
Brett J Hart |
BUY
Grant, award, or other acquisition
|
Direct |
1,322
+6.75%
|
-
|
May 03
2024
|
Roxanne S Austin |
BUY
Grant, award, or other acquisition
|
Direct |
1,322
+3.43%
|
-
|
May 03
2024
|
Thomas C Freyman |
BUY
Grant, award, or other acquisition
|
Direct |
1,322
+1.04%
|
-
|
May 03
2024
|
Robert J Alpern |
BUY
Grant, award, or other acquisition
|
Direct |
1,322
+3.7%
|
-
|
May 03
2024
|
Edward J Rapp |
BUY
Grant, award, or other acquisition
|
Direct |
1,322
+4.05%
|
-
|
May 03
2024
|
Susan E Quaggin |
BUY
Grant, award, or other acquisition
|
Direct |
1,322
+50.0%
|
-
|
Mar 20
2024
|
Nicholas Donoghoe EVP, CHIEF BUS/STRAT OFFICER |
SELL
Open market or private sale
|
Direct |
21,082
-27.38%
|
$3,710,432
$176.3 P/Share
|
Mar 18
2024
|
Jeffrey Ryan Stewart EVP, CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
58,949
-19.5%
|
$10,492,922
$178.86 P/Share
|
Mar 18
2024
|
Jeffrey Ryan Stewart EVP, CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
26,110
+17.88%
|
$1,592,710
$61.36 P/Share
|
Mar 01
2024
|
Timothy J. Richmond EVP, CHIEF HR OFFICER |
SELL
Open market or private sale
|
Direct |
75,680
-34.96%
|
$13,395,360
$177.04 P/Share
|
Mar 01
2024
|
Timothy J. Richmond EVP, CHIEF HR OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
45,700
+33.8%
|
$2,787,700
$61.36 P/Share
|
Feb 29
2024
|
Perry C Siatis EVP, GC AND SECRETARY |
SELL
Open market or private sale
|
Direct |
9,891
-28.32%
|
$1,750,707
$177.54 P/Share
|
Feb 29
2024
|
Robert A. Michael PRES & CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
68,879
-22.64%
|
$12,122,704
$176.45 P/Share
|
Feb 29
2024
|
Robert A. Michael PRES & CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
21,560
+6.24%
|
$1,250,480
$58.11 P/Share
|
Feb 29
2024
|
Kevin K Buckbee SVP, CONTROLLER |
SELL
Open market or private sale
|
Direct |
5,144
-42.42%
|
$905,344
$176.65 P/Share
|
Feb 28
2024
|
Richard A Gonzalez CHAIRMAN OF THE BOARD AND CEO |
SELL
Open market or private sale
|
Direct |
138,616
-21.08%
|
$24,535,032
$177.27 P/Share
|
Feb 28
2024
|
Richard A Gonzalez CHAIRMAN OF THE BOARD AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
110,249
-14.36%
|
$19,624,322
$178.99 P/Share
|
Feb 28
2024
|
Nicholas Donoghoe EVP, CHIEF BUS/STRAT OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
16,771
-17.89%
|
$2,985,238
$178.99 P/Share
|
Feb 28
2024
|
Roopal Thakkar SVP, CMO, GLOBAL THERAPEUTICS |
SELL
Payment of exercise price or tax liability
|
Direct |
4,914
-17.44%
|
$874,692
$178.99 P/Share
|
Feb 28
2024
|
Thomas J Hudson SVP, CSO, GLOBAL RESEARCH |
SELL
Payment of exercise price or tax liability
|
Direct |
20,634
-16.13%
|
$3,672,852
$178.99 P/Share
|
Feb 28
2024
|
Timothy J. Richmond EVP, CHIEF HR OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
23,847
-35.24%
|
$4,244,766
$178.99 P/Share
|
Feb 28
2024
|
Azita Saleki Gerhardt EVP, CHIEF OPERATIONS OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
23,966
-9.82%
|
$4,265,948
$178.99 P/Share
|
Feb 28
2024
|
Jeffrey Ryan Stewart EVP, CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
26,121
-21.79%
|
$4,649,538
$178.99 P/Share
|
Feb 28
2024
|
Perry C Siatis EVP, GC AND SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
7,885
-27.99%
|
$1,403,530
$178.99 P/Share
|
Feb 28
2024
|
Robert A. Michael PRES & CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
37,638
-20.5%
|
$6,699,564
$178.99 P/Share
|
Feb 28
2024
|
Kevin K Buckbee SVP, CONTROLLER |
SELL
Payment of exercise price or tax liability
|
Direct |
5,339
-27.79%
|
$950,342
$178.99 P/Share
|
Feb 28
2024
|
Scott T Reents EVP, CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
11,634
-42.99%
|
$2,070,852
$178.99 P/Share
|
Feb 27
2024
|
Richard A Gonzalez CHAIRMAN OF THE BOARD AND CEO |
SELL
Bona fide gift
|
Direct |
4,195
-0.27%
|
-
|
Feb 23
2024
|
Scott T Reents EVP, CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
14,140
-34.32%
|
$2,502,780
$177.44 P/Share
|
Feb 23
2024
|
Scott T Reents EVP, CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
14,140
+25.55%
|
$862,540
$61.36 P/Share
|
Feb 23
2024
|
Perry C Siatis EVP, GC AND SECRETARY |
SELL
Open market or private sale
|
Direct |
13,753
-32.8%
|
$2,434,281
$177.51 P/Share
|
Feb 23
2024
|
Perry C Siatis EVP, GC AND SECRETARY |
BUY
Exercise of conversion of derivative security
|
Direct |
13,753
+10.89%
|
$1,829,149
$133.36 P/Share
|
Feb 21
2024
|
Azita Saleki Gerhardt EVP, CHIEF OPERATIONS OFFICER |
SELL
Open market or private sale
|
Direct |
52,870
-17.81%
|
$9,146,510
$173.71 P/Share
|
Feb 21
2024
|
Azita Saleki Gerhardt EVP, CHIEF OPERATIONS OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
52,870
+15.12%
|
$3,066,460
$58.88 P/Share
|
Feb 15
2024
|
Timothy J. Richmond EVP, CHIEF HR OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
53,827
+18.31%
|
-
|
Feb 15
2024
|
Azita Saleki Gerhardt EVP, CHIEF OPERATIONS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
54,095
+5.41%
|
-
|
Feb 15
2024
|
Richard A Gonzalez CHAIRMAN OF THE BOARD AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
248,865
+7.8%
|
-
|
Feb 15
2024
|
Robert A. Michael PRES & CHIEF OPERATING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
84,957
+11.09%
|
-
|
Feb 15
2024
|
Jeffrey Ryan Stewart EVP, CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
58,960
+11.92%
|
-
|
Feb 15
2024
|
Thomas J Hudson SVP, CSO, GLOBAL RESEARCH |
BUY
Grant, award, or other acquisition
|
Direct |
46,572
+8.69%
|
-
|
Feb 15
2024
|
Scott T Reents EVP, CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
26,256
+25.36%
|
-
|
Feb 15
2024
|
Perry C Siatis EVP, GC AND SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
17,796
+16.11%
|
-
|
Feb 15
2024
|
Roopal Thakkar SVP, CMO, GLOBAL THERAPEUTICS |
BUY
Grant, award, or other acquisition
|
Direct |
17,796
+16.11%
|
-
|